Excess Mortality Attributable to Hospital-Acquired Antimicrobial-Resistant Infections: A 2-Year Prospective Surveillance Study in Northeast Thailand

Cherry Lim, Prapit Teparrukkul, Somboon Nuntalohit, Somsamai Boonsong, Jiraphorn Nilsakul, Pramot Srisamang, Benn Sartorius, Nicholas J White, Nicholas P J Day, Ben S Cooper, Direk Limmathurotsakul, Cherry Lim, Prapit Teparrukkul, Somboon Nuntalohit, Somsamai Boonsong, Jiraphorn Nilsakul, Pramot Srisamang, Benn Sartorius, Nicholas J White, Nicholas P J Day, Ben S Cooper, Direk Limmathurotsakul

Abstract

Background: Quantifying the excess mortality attributable to antimicrobial-resistant (AMR) bacterial infections is important for assessing the potential benefit of preventive interventions and for prioritization of resources. However, there are few data from low- and middle-income countries.

Methods: We conducted a 2-year prospective surveillance study to estimate the excess mortality attributable to AMR infections for all types of hospital-acquired infection (HAI), and included bacterial species that were both locally relevant and included in the World Health Organization priority list. Twenty-eight-day mortality was measured. Excess mortality and population attributable fraction (PAF) of mortality caused by AMR infections compared to antimicrobial-susceptible (AMS) infections, adjusted for predefined confounders, were calculated.

Results: We enrolled 2043 patients with HAIs. The crude 28-day mortality of patients with AMR and AMS infections was 35.5% (491/1385) and 23.1% (152/658), respectively. After adjusting for prespecified confounders, the estimated excess mortality attributable to AMR infections was 7.7 (95% confidence interval [CI], 2.2-13.2) percentage points. This suggests that 106 (95% CI, 30-182) deaths among 1385 patients with AMR infections might have been prevented if all of the AMR infections in this study were AMS infections. The overall PAF was 16.3% (95% CI, 1.2%-29.1%). Among the bacteria under evaluation, carbapenem-resistant Acinetobacter baumannii was responsible for the largest number of excess deaths. Among all types of infection, urinary tract infections were associated with the highest number of excess deaths, followed by lower respiratory tract infections and bloodstream infections.

Conclusions: Estimating and monitoring excess mortality attributable to AMR infections should be included in national action plans to prioritize targets of preventive interventions.

Clinical trials registration: NCT03411538.

Keywords: antimicrobial resistance; excess mortality; hospital-acquired infection; nosocomial infection.

© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

Figures

Figure 1.
Figure 1.
Study flow diagram. Infections with methicillin-resistant Staphylococcus aureus, ampicillin-resistant Enterococcus faecium and Enterococcus faecalis, third-generation cephalosporin-resistant Escherichia coli and Klebsiella pneumoniae, and carbapenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii are defined as antimicrobial-resistant infections. Infections caused by the bacteria that was susceptible to the corresponding antibiotic of interest are defined as antimicrobial-susceptible (AMS) infections. *Of the 658 patients with AMS infection, 11 were lost to follow-up. Among these 11 patients, 5 were discharged against medical advice with health condition not improving and were assumed to have died within 28 days of follow-up since the first date of culture-positive specimen collection. **Of the 1385 patients, 28 were lost to follow-up. Among these 28 patients, 23 were discharged against medical advice with health condition not improving, and were assumed to have died within 28 days of follow-up since the first date of culture-positive specimen collection. Abbreviations: AMR, antimicrobial-resistant; AMS, antimicrobial-susceptible; HAI, hospital-acquired infection.
Figure 2.
Figure 2.
A level plot illustrating number of patients with hospital-acquired infections by each causative bacteria and type of infection. “>1 type of infection” is defined as infections that occurred with ≥2 types of infection including bloodstream infection (BSI), lower respiratory tract infection (LRTI), surgical site infection (SSI), urinary tract infection (UTI), and infections at other body sites (OTH). *Polymicrobial is defined as infections with >1 of the bacteria included in the evaluation.
Figure 3.
Figure 3.
Expected mortality if all infections caused by each causative bacteria were antimicrobial susceptible (AMS; gray) or antimicrobial resistant (black). Excess mortality (percentage points; 95% confidence interval) is defined as the mortality in the study cohort that would be prevented if the infections of the specific type were AMS infections, adjusted for the predefined confounding factors. Polymicrobial is defined as infections with >1 of the bacteria in the evaluation. Abbreviations: 3GCREC, third-generation cephalosporin-resistant Escherichia coli; 3GCRKP, third-generation cephalosporin-resistant Klebsiella pneumoniae; 3GCSEC, third-generation cephalosporin-susceptible Escherichia coli; 3GCSKP, third-generation cephalosporin-susceptible Klebsiella pneumoniae; AMPREfc, ampicillin-resistant Enterococcus faecalis; AMPREfm, ampicillin-resistant Enterococcus faecium; AMPSEfc, ampicillin-susceptible Enterococcus faecalis; AMPSEfm, ampicillin-susceptible Enterococcus faecium; AMR, antimicrobial resistant; AMS, antimicrobial-susceptible; CRAB, carbapenem-resistant Acinetobacter baumannii; CRPA, carbapenem-resistant Pseudomonas aeruginosa; CSAB, carbapenem-susceptible Acinetobacter baumannii; CSPA, carbapenem-susceptible Pseudomonas aeruginosa; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus.
Figure 4.
Figure 4.
Expected mortality if all infections for each type of infection were antimicrobial susceptible (AMS; gray) or antimicrobial resistant (black). Excess mortality (percentage points; 95% confidence interval) is defined as the mortality in the study cohort that would be prevented if the infections of the specific type were AMS infections, adjusted for the predefined confounding factors. Abbreviations: AMR, antimicrobial-resistant; AMS, antimicrobial-susceptible; BSI, bloodstream infection; LRTI, lower respiratory tract infection; OTH, other infections; SSI, surgical site infection; UTI, urinary tract infection; >1 type of infection, infections that occurred with ≥2 types including BSI, LRTI, SSI, UTI, and OTH.

References

    1. O’Neill J. The Review on Antimicrobial Resistance. Tackling drug-resistant infections globally: final report and recommendation. 2016. . Accessed 1 April 2022.
    1. World Health Organization . GLASS method for estimating attributable mortality of antimicrobial resistant bloodstream infections. Geneva, Switzerland: WHO; 2020.
    1. Martone WJ, Jarvis WR, Edwards JR, Culver DH, Haley RW. Incidence and nature of endemic and epidemic nosocomial infections. In: Bennett JV, Brachman PS, eds. Hospital Infections, 4th ed. Philadelphia, PA: Lippincott-Raven; 1998:461––76..
    1. European Centre for Disease Prevention and Control and European Medicines Agency. ECDC/EMA joint technical report. The bacterial challenge: time to react. Stockholm: ECDC/EMA; 2009.
    1. Lim C, Takahashi E, Hongsuwan M, et al. Epidemiology and burden of multidrug-resistant bacterial infection in a developing country. Elife 2016; 5.
    1. Limmathurotsakul D, Dunachie S, Fukuda K, et al. ; Surveillance and Epidemiology of Drug Resistant Infectious Consortium (SEDRIC). Improving the estimation of the global burden of antimicrobial resistant infections. Lancet Infect Dis 2019. doi:10.1016/S1473-3099(19)30276-2.
    1. de Kraker ME, Stewardson AJ, Harbarth S. Will 10 million people die a year due to antimicrobial resistance by 2050? PLoS Med 2016; 13:e1002184. doi:10.1371/journal.pmed.1002184.
    1. Centers for Disease Control and Prevention . Antibiotic resistance threats in the United States, 2013. . Accessed 4 February 2016.
    1. Cassini A, Hogberg LD, Plachouras D, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis 2019; 19:56–66. doi:10.1016/S1473-3099(18)30605-4.
    1. Antimicrobial Resistance Collaborators . Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 2022; 399:629–55. doi:10.1016/S0140-6736(21)02724-0.
    1. Naylor NR, Atun R, Zhu N, et al. Estimating the burden of antimicrobial resistance: a systematic literature review. Antimicrob Resist Infect Control 2018; 7:58. doi:10.1186/s13756-018-0336-y.
    1. Lim C, Ashley EA, Hamers RL, et al. Surveillance strategies using routine microbiology for antimicrobial resistance in low- and middle-income countries. Clin Microbiol Infect 2021; 27:1391–9. doi:10.1016/j.cmi.2021.05.037.
    1. Centers for Disease Control and Prevention . Antibiotic resistance threats in the United States, 2019. . Accessed 3 December 2021.
    1. Lim C, Hantrakun V, Teerawattanasook N, et al. Impact of low blood culture usage on rates of antimicrobial resistance. J Infect 2021; 82:355–62. doi:10.1016/j.jinf.2020.10.040.
    1. Centers for Disease Control and Prevention . CDC/NHSN surveillance definitions for specific types of infections. 2021. . Accessed 22 January 2021.
    1. Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 2016; 63:e61–111. doi:10.1093/cid/ciw353.
    1. European Centre for Disease Prevention and Control . Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals—protocol version 5.3. Stockholm: ECDC; 2016.
    1. Lopez-Luis BA, Sifuentes-Osornio J, Lambrano-Castillo D, et al. Risk factors and outcomes associated with vancomycin-resistant Enterococcus faecium and ampicillin-resistant Enterococcus faecalis bacteraemia: a 10-year study in a tertiary-care centre in Mexico City. J Glob Antimicrob Resist 2021; 24:198–204. doi:10.1016/j.jgar.2020.12.005.
    1. Hernán MA, Robins JM. Causal inference: what if. Boca Raton, FL: Chapman & Hall/CRC; 2020.
    1. Greenland S, Robins JM. Conceptual problems in the definition and interpretation of attributable fractions. Am J Epidemiol 1988; 128:1185–97. doi:10.1093/oxfordjournals.aje.a115073.
    1. Greenland S. Relation of probability of causation to relative risk and doubling dose: a methodologic error that has become a social problem. Am J Public Health 1999; 89:1166–9. doi:10.2105/AJPH.89.8.1166.
    1. von Cube M, Timsit JF, Schumacher M, Motschall E, Schumacher M. Quantification and interpretation of attributable mortality in core clinical infectious disease journals. Lancet Infect Dis 2020; 20:e299–306. doi:10.1016/S1473-3099(20)30485-0.
    1. Kritsotakis EI, Kontopidou F, Astrinaki E, Roumbelaki M, Ioannidou E, Gikas A. Prevalence, incidence burden, and clinical impact of healthcare-associated infections and antimicrobial resistance: a national prevalent cohort study in acute care hospitals in Greece. Infect Drug Resist 2017; 10:317–28. doi:10.2147/IDR.S147459.
    1. Fortun J, Coque TM, Martin-Davila P, et al. Risk factors associated with ampicillin resistance in patients with bacteraemia caused by Enterococcus faecium. J Antimicrob Chemother 2002; 50:1003–9. doi:10.1093/jac/dkf216.
    1. Aamodt H, Mohn SC, Maselle S, et al. Genetic relatedness and risk factor analysis of ampicillin-resistant and high-level gentamicin-resistant enterococci causing bloodstream infections in Tanzanian children. BMC Infect Dis 2015; 15:107. doi:10.1186/s12879-015-0845-8.
    1. Temkin E, Carmeli Y. Zero or more: methodological challenges of counting and estimating deaths related to antibiotic-resistant infections. Clin Infect Dis 2019; 69:2029–34. doi:10.1093/cid/ciz414.
    1. de Kraker MEA, Lipsitch M. Burden of antimicrobial resistance: compared to what? Epidemiol Rev 2021; 43:53–64.
    1. Lim C, Mo Y, Teparrukkul P, et al. Effect of delays in concordant antibiotic treatment on mortality in patients with hospital-acquired Acinetobacter species bacteraemia: emulating a target randomised trial with 13 year retrospective cohort. Am J Epidemiol 2021; 190:2395–404. doi:10.1093/aje/kwab158.

Source: PubMed

3
Subscribe